144 related articles for article (PubMed ID: 37356372)
1. Alpha-tocopheryl succinate and doxorubicin-loaded liposomes improve drug uptake and tumor accumulation in a murine breast tumor model.
Boratto FA; Lages EB; Loures CMC; Sabino AP; Malachias A; Townsend DM; Branco De Barros AL; Miranda Ferreira LA; Amaral Leite E
Biomed Pharmacother; 2023 Sep; 165():115034. PubMed ID: 37356372
[TBL] [Abstract][Full Text] [Related]
2. Alpha-tocopheryl succinate improves encapsulation, pH-sensitivity, antitumor activity and reduces toxicity of doxorubicin-loaded liposomes.
Boratto FA; Franco MS; Barros ALB; Cassali GD; Malachias A; Ferreira LAM; Leite EA
Eur J Pharm Sci; 2020 Mar; 144():105205. PubMed ID: 31874285
[TBL] [Abstract][Full Text] [Related]
3. α-Tocopherol Polyethylene Glycol 1000 Succinate-Based Cationic Liposome for the Intracellular Delivery of Doxorubicin in MDA-MB-231 Triple-Negative Breast Cancer Cell Line.
Sandal P; Patel P; Singh D; Gupta GD; Kurmi BD
Assay Drug Dev Technol; 2023; 21(8):345-356. PubMed ID: 38010987
[No Abstract] [Full Text] [Related]
4. α- Tocopherol succinate loaded nano-structed lipid carriers improves antitumor activity of doxorubicin in breast cancer models in vivo.
Fernandes RS; Silva JO; Seabra HA; Oliveira MS; Carregal VM; Vilela JMC; Andrade MS; Townsend DM; Colletti PM; Leite EA; Cardoso VN; Ferreira LAM; Rubello D; Barros ALB
Biomed Pharmacother; 2018 Jul; 103():1348-1354. PubMed ID: 29864917
[TBL] [Abstract][Full Text] [Related]
5. Co-delivery of doxorubicin, docosahexaenoic acid, and α-tocopherol succinate by nanostructured lipid carriers has a synergistic effect to enhance antitumor activity and reduce toxicity.
Lages EB; Fernandes RS; Silva JO; de Souza ÂM; Cassali GD; de Barros ALB; Miranda Ferreira LA
Biomed Pharmacother; 2020 Dec; 132():110876. PubMed ID: 33113428
[TBL] [Abstract][Full Text] [Related]
6. pH-sensitive doxorubicin-tocopherol succinate prodrug encapsulated in docosahexaenoic acid-based nanostructured lipid carriers: An effective strategy to improve pharmacokinetics and reduce toxic effects.
Lages EB; Fernandes RS; Andrade MMS; Paiyabhroma N; de Oliveira RB; Fernandes C; Cassali GD; Sicard P; Richard S; Branco de Barros AL; Ferreira LAM
Biomed Pharmacother; 2021 Dec; 144():112373. PubMed ID: 34794238
[TBL] [Abstract][Full Text] [Related]
7. PEGylated phospholipid micelles containing D-α-tocopheryl succinate as multifunctional nanocarriers for enhancing the antitumor efficacy of doxorubicin.
Jiang W; Fan Q; Wang J; Zhang B; Hao T; Chen Q; Li L; Chen L; Cui H; Li Z
Int J Pharm; 2021 Sep; 607():120979. PubMed ID: 34371151
[TBL] [Abstract][Full Text] [Related]
8. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
[TBL] [Abstract][Full Text] [Related]
9. The effect of dual-functional hyaluronic acid-vitamin E succinate micelles on targeting delivery of doxorubicin.
Wang J; Ma W; Guo Q; Li Y; Hu Z; Zhu Z; Wang X; Zhao Y; Chai X; Tu P
Int J Nanomedicine; 2016; 11():5851-5870. PubMed ID: 27853369
[TBL] [Abstract][Full Text] [Related]
10. Liposomes co-encapsulating doxorubicin and glucoevatromonoside derivative induce synergic cytotoxic response against breast cancer cell lines.
Novais MVM; Gomes ER; Miranda MC; Silva JO; Gomes DA; Braga FC; Pádua RM; Oliveira MC
Biomed Pharmacother; 2021 Apr; 136():111123. PubMed ID: 33486211
[TBL] [Abstract][Full Text] [Related]
11. Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.
Shahin M; Soudy R; Aliabadi HM; Kneteman N; Kaur K; Lavasanifar A
Biomaterials; 2013 May; 34(16):4089-4097. PubMed ID: 23465829
[TBL] [Abstract][Full Text] [Related]
12. D-α-tocopherol polyethylene glycol 1000 succinate-modified liposomes with an siRNA corona confer enhanced cellular uptake and targeted delivery of doxorubicin via tumor priming.
Tan X; Fang Y; Ren Y; Li Y; Wu P; Yang X; Liu W
Int J Nanomedicine; 2019; 14():1255-1268. PubMed ID: 30863058
[TBL] [Abstract][Full Text] [Related]
13. Lipoic acid-derived cross-linked liposomes for reduction-responsive delivery of anticancer drug.
Ling L; Ismail M; Du Y; Yao C; Li X
Int J Pharm; 2019 Apr; 560():246-260. PubMed ID: 30769133
[TBL] [Abstract][Full Text] [Related]
14. Dual-pH Sensitive Charge-Reversal Drug Delivery System for Highly Precise and Penetrative Chemotherapy.
Chen W; Li J; Xing Y; Wang X; Zhang H; Xia M; Wang D
Pharm Res; 2020 Jul; 37(7):134. PubMed ID: 32642819
[TBL] [Abstract][Full Text] [Related]
15. Cell-penetrating corosolic acid liposome as a functional carrier for delivering chemotherapeutic drugs.
Li X; Widjaya AS; Liu J; Liu X; Long Z; Jiang Y
Acta Biomater; 2020 Apr; 106():301-313. PubMed ID: 32081779
[TBL] [Abstract][Full Text] [Related]
16. In Vitro and In Vivo Effect of pH-Sensitive PLGA-TPGS-Based Hybrid Nanoparticles Loaded with Doxorubicin for Breast Cancer Therapy.
Fernandes RS; Arribada RG; Silva JO; Silva-Cunha A; Townsend DM; Ferreira LAM; Barros ALB
Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36365212
[TBL] [Abstract][Full Text] [Related]
17. A pH-sensitive prodrug strategy to co-deliver DOX and TOS in TPGS nanomicelles for tumor therapy.
Xiong S; Wang Z; Liu J; Deng X; Xiong R; Cao X; Xie Z; Lei X; Chen Y; Tang G
Colloids Surf B Biointerfaces; 2019 Jan; 173():346-355. PubMed ID: 30316081
[TBL] [Abstract][Full Text] [Related]
18. Development and optimization of TPGS-based stealth liposome of doxorubicin using Box-Behnken design: characterization, hemocompatibility, and cytotoxicity evaluation in breast cancer cells.
Kurmi BD; Paliwal SR
J Liposome Res; 2022 Jun; 32(2):129-145. PubMed ID: 33724151
[TBL] [Abstract][Full Text] [Related]
19. Development of doxorubicin hydrochloride loaded pH-sensitive liposomes: Investigation on the impact of chemical nature of lipids and liposome composition on pH-sensitivity.
Rehman AU; Omran Z; Anton H; Mély Y; Akram S; Vandamme TF; Anton N
Eur J Pharm Biopharm; 2018 Dec; 133():331-338. PubMed ID: 30414990
[TBL] [Abstract][Full Text] [Related]
20. Overcoming multidrug resistance by intracellular drug release and inhibiting p-glycoprotein efflux in breast cancer.
Mao J; Qiu L; Ge L; Zhou J; Ji Q; Yang Y; Long M; Wang D; Teng L; Chen J
Biomed Pharmacother; 2021 Feb; 134():111108. PubMed ID: 33341670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
